Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : REFILE-UPDATE 2-EU has not ordered AstraZeneca vaccines beyond June - Commissioner

05/09/2021 | 08:27am EDT

PARIS, May 9 (Reuters) - The European Union has not made any new orders for AstraZeneca vaccines beyond June when their contract ends, European Internal Market Commissioner Thierry Breton said on Sunday, after the EU signed a deal with Pfizer-BioNTech.

Breton also said he expected the costs of the Pfizer-BioNTech vaccines to be higher than the earlier versions.

The Commission last month launched legal action against AstraZeneca for not respecting its contract for the supply of COVID-19 vaccines and for not having a "reliable" plan to ensure timely deliveries. "We did not renew the order after June. We’ll see what happens," Breton told France Inter radio. He did not rule out a potential renewal at a later stage.

Concerns have risen on potential side-effects of the Anglo-Swedish COVID-19 vaccine.

Europe's medicines regulator said on Friday it is reviewing reports of a rare nerve-degenerating disorder in people who received the shots, a move that comes after it found the vaccine may have caused very rare blood clotting cases.

While the regulator has maintained that the benefits of the AstraZeneca vaccine outweigh any risks, several European countries have limited use to older age groups or suspended use altogether.

In answer to a question at the European Parliament in Strasbourg, French President Emmanuel Macron welcomed the move towards what he sees are more effective vaccines against new variants of COVID-19, calling it "pragmatic". "We are vaccinating with this vaccine (AstraZeneca) in France and in Europe. We must continue to do this because it will help us get out of the crisis." he said.

"But for future orders, in order to respond in particular to variants, we see that other vaccines are now more effective, so this signals a European pragmatism which I welcome."

The European Union signed a new contract with Pfizer-BioNTech to receive 1.8 billion doses of COVID-19 vaccines for 2021-2023, to cover booster shots, donations and reselling of doses, the European Commission said on Friday.

An increase in prices for second generation vaccines could be justified by the extra research required and potential changes to industrial equipment, Breton said.

"There may be a little extra cost but I will let the competent authorities unveil it in due course," he told France Inter radio. (Reporting by Sybille de La Hamaide; Editing by Toby Chopra, Andrew Cawthorne and Raissa Kasolowsky)


© Reuters 2021
All news about ASTRAZENECA PLC
03:36pHUTCHMED CHINA  : AstraZeneca Drug Savolitinib Wins Conditional Approval in Chin..
MT
11:35aASTRAZENECA  : Denmark to Donate AstraZeneca COVID-19 Jabs to Kenya
MT
08:41aASTRAZENECA  : Fancy a Covid jab? Here are all the free walk-in sites open in Lo..
AQ
07:35aASTRAZENECA  : SPRINT Phase II trial showed Koselugo reduced tumour volume, redu..
PU
07:06aASTRAZENECA  : Come Get Your Second Jab, Govt Tells Kenyans on Receiving Covid V..
AQ
06:05aLondon Shares Trade Flat; Crude Gains Lift Oil Stocks
DJ
04:42aASTRAZENECA  : India says new COVID variant is a concern
RE
04:24aASTRAZENECA  : Gets European Commission's Conditional Approval for Koselugo in P..
MT
02:43aTHE LATEST : Georgia governor to end health emergency July 1
AQ
02:31aASTRAZENECA  : Merck & Co. Win Conditional EU Nod for Rare Disease Drug in Child..
MT
More news
Financials (USD)
Sales 2021 30 988 M - -
Net income 2021 4 559 M - -
Net Debt 2021 10 731 M - -
P/E ratio 2021 36,7x
Yield 2021 2,45%
Capitalization 153 B 153 B -
EV / Sales 2021 5,28x
EV / Sales 2022 4,55x
Nbr of Employees 76 100
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 116,46 $
Average target price 132,57 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.01%153 616
JOHNSON & JOHNSON3.96%431 456
ROCHE HOLDING AG12.99%328 650
PFIZER, INC.7.61%220 661
NOVARTIS AG3.00%210 615
ABBVIE INC.7.05%202 639